Next Biomedical Statistics

Total Valuation

Next Biomedical has a market cap or net worth of KRW 365.31 billion.

Market Cap	365.31B
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Next Biomedical has 8.13 million shares outstanding. The number of shares has increased by 24.75% in one year.

Current Share Class	8.13M
Shares Outstanding	8.13M
Shares Change (YoY)	+24.75%
Shares Change (QoQ)	-8.51%
Owned by Insiders (%)	31.61%
Owned by Institutions (%)	7.61%
Float	5.04M

Valuation Ratios

The trailing PE ratio is 130.75.

PE Ratio	130.75
Forward PE	n/a
PS Ratio	33.38
PB Ratio	8.06
P/TBV Ratio	8.12
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.85, with a Debt / Equity ratio of 0.24.

Current Ratio	3.85
Quick Ratio	3.60
Debt / Equity	0.24
Debt / EBITDA	n/a
Debt / FCF	-11.50
Interest Coverage	-7.43

Financial Efficiency

Return on equity (ROE) is 9.02% and return on invested capital (ROIC) is -5.47%.

Return on Equity (ROE)	9.02%
Return on Assets (ROA)	-5.17%
Return on Invested Capital (ROIC)	-5.47%
Return on Capital Employed (ROCE)	-7.83%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.25
Inventory Turnover	1.62

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	43,076.00
200-Day Moving Average	42,090.75
Relative Strength Index (RSI)	58.65
Average Volume (20 Days)	108,371

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Next Biomedical had revenue of KRW 10.95 billion and earned 2.79 billion in profits.

Revenue	10.95B
Gross Profit	6.76B
Operating Income	-3.68B
Pretax Income	2.79B
Net Income	2.79B
EBITDA	-3.18B
EBIT	-3.68B
Earnings Per Share (EPS)	-255.76

Full Income Statement

Balance Sheet

The company has 41.46 billion in cash and 10.80 billion in debt, giving a net cash position of 30.66 billion or 3,772.09 per share.

Cash & Cash Equivalents	41.46B
Total Debt	10.80B
Net Cash	30.66B
Net Cash Per Share	3,772.09
Equity (Book Value)	45.31B
Book Value Per Share	5,601.40
Working Capital	34.67B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -436.34 million and capital expenditures -502.91 million, giving a free cash flow of -939.25 million.

Operating Cash Flow	-436.34M
Capital Expenditures	-502.91M
Free Cash Flow	-939.25M
FCF Per Share	-115.57

Full Cash Flow Statement

Margins

Gross margin is 61.76%, with operating and profit margins of -33.61% and 25.53%.

Gross Margin	61.76%
Operating Margin	-33.61%
Pretax Margin	25.53%
Profit Margin	25.53%
EBITDA Margin	-29.09%
EBIT Margin	-33.61%
FCF Margin	n/a

Dividends & Yields

Next Biomedical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-24.75%
Shareholder Yield	n/a
Earnings Yield	0.76%
FCF Yield	-0.26%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Next Biomedical has an Altman Z-Score of 13.44 and a Piotroski F-Score of 5.

Altman Z-Score	13.44
Piotroski F-Score	5